80%Confidence
0Views
FDASource
2026-03-29Date
Summary
Rising Pharma's Temozolomide recall due to stability testing failures indicates potential quality issues in oncology medications, which are particularly sensitive to stability concerns. The Taiwan manufacturing origin suggests possible supply chain quality control challenges that may affect other products from this source.
Actionable: Evaluate the stability testing protocols for all oncology medications in inventory and consider additional testing for products from this manufacturer.
AI Confidence: 80%
Data Points
firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now